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Metabolic and Addiction Indices
in Patients on Opioid Agonist
Medication-Assisted Treatment: A
Comparison of Buprenorphine and
Methadone
Igor Elman1*, Margaret Howard2, Jacob T. Borodovsky3, David Mysels4, David Rott5,
David Borsook6 & Mark Albanese7
Metabolic hormones stabilize brain reward and motivational circuits, whereas excessive opioid
consumption counteracts this effect and may impair metabolic function. Here we addressed the role of
metabolic processes in the course of the agonist medication-assisted treatment for opioid use disorder
(OUD) with buprenorphine or methadone. Plasma lipids, hemoglobin A1C, body composition, the
oral glucose tolerance test (oGTT) and the Sweet Taste Test (STT) were measured in buprenorphine(n = 26) or methadone (n = 32)- treated subjects with OUD. On the whole, the subjects in both groups
were overweight or obese and insulin resistant; they displayed similar oGTT and STT performance. As
compared to methadone-treated subjects, those on buprenorphine had significantly lower rates of
metabolic syndrome (MetS) along with better values of the high-density lipoproteins (HDL). Subjects
with- vs. without MetS tended to have greater addiction severity. Correlative analyses revealed that
more buprenorphine exposure duration was associated with better HDL and opioid craving values. In
contrast, more methadone exposure duration was associated with worse triglycerides-, HDL-, blood
pressure-, fasting glucose- and hemoglobin A1C values. Buprenorphine appears to produce beneficial
HDL- and craving effects and, contrary to methadone, its role in the metabolic derangements is
not obvious. Our data call for further research aimed at understanding the distinctive features of
buprenorphine metabolic effects vis-à-vis those of methadone and their potential role in these drugs’
unique therapeutic profiles.
Opioid use disorder (OUD) is an ominous public health problem afflicting about 16 million people worldwide 1.
In the US, OUD constitutes the seventh cause for disability-adjusted life-years2–4; including opioids’ propensity5
for the excessive body weight gain (BWG) and its medical sequelae in the form of the ‘Metabolic Syndrome’
(MetS)5–7, that is to say, a cluster of interrelated cardiometabolic risk factors comprised of insulin resistance,
impaired glucose tolerance, dyslipidemia, abdominal adiposity and hypertension8–10. Consequently, even though
medication-assisted treatment (MAT) via opioid agonist replacement with long-acting opioids namely, buprenorphine and methadone, usually yields positive clinical outcomes in terms of overdose mortality, infectious diseases, crime, and societal ties11–14 concerns have been raised about further worsening of the metabolic status5.
There are several lines of evidence that link OUD to metabolic derangements. With regard to genetic
antecedents, the TCF7L2 gene codes a transcription factor implicated 15,16 in non-insulin-dependent
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diabetes mellitus (NIDDM) and in µ opioid receptor-mediated drug intake17. Additionally, melanocortin-418,
orexin-119 and OPRM120 genes, involved in appetite and in obesity21,22 also underlie opioid consumption19,23.
Likewise, the appetite-regulating gene24 controls the expression of the dopamine D2 receptor gene playing a pivotal role in addiction21,25. Biochemically, opioids (e.g., methadone) respectively inhibit and enhance
glycolytic- (hexokinase and phosphofructokinase) and gluconeogenesis enzymes (glucose-6-phoaphatase and
fructose-1,6-biphosphatase) in the liver and thus produce a state akin to NIDDM26. From the digestive perspective, opioids interfere with gastrointestinal motility and with proper food absorption27. The endocrine aspects
include counterregulatory hormones’ secretion evoked by methadone28–30 and alterations in leptin, adiponectin
and resistin 31, clinically manifested as NIDDM. Opioids also cause gonadal insufficiency6,32, another major contributor to MetS33, as well as a reduction in insulin secretion34–36 and desensitization of the peripheral insulin
receptors37.
At the homeostatic level, enhanced µ-opioidergic opioid neurotransmission38 respectively boosts and suppresses orexigenic and anorexigenic neuropeptides39–41. Opioids likewise enhance hedonic preference for sweet
and fatty foods42,43 and so are involved in the pathophysiology of food craving and addiction21,44,45. Metabolic
hormones’ (e.g., insulin) secretion during physiologically-determined anabolism restrains (i.e., increases refractoriness) of the hedonic/motivational neural pathways driving the consumption of both, palatable food46–48,
and addictive drugs21. Caloric deprivation and consequent catabolism conversely predispose for drug seeking
and relapse49. The above metabolic restraint by insulin is, however, rendered inefficient by sweet and fatty ‘junk’
food46,47,50 that is avidly consumed by opioid addicts43,51,52 attributable to the exaggerated opioidergic activity
enhancing the hedonic appeal of the unhealthy diets21. Therefore, a common result in vulnerable individuals
could be a feedforward loop whereby high caloric content palatable food produces additional deterioration in the
regulatory mechanisms prompting unhealthy eating patterns and opioid consumption to the extent that a bona
fide MetS, OUD and comorbid conditions53 may ensue.
MetS represents a complex pathophysiological condition that may develop in OUD patients54–57 even independent of MAT, from increased caloric intake, decreased energy expenditure owing to reduced physical activity
or a combination of both8,21. This assertion is however undermined by: (1) preponderance of studies reporting
low body weight in short half-life opioid (e.g., heroin) abusers who are not on MAT agonist therapy58–61 even
in the face of glucoregulatory abnormalities62–64; and (2) excessive BWG consistently noted in OUD patients
following the initiation of methadone65–71 and to a lesser degree buprenorphine6,7,72 treatment. Nonetheless, the
debate about the issue is still ongoing73 with a number of reports on the opposite directionality of the metabolic
responses74,75, including hemoglobin A1C level decreases in buprenorphine-maintained NIDDM patients76 in
conjunction with heightened insulin sensitivity in methadone-treated OUD patients77 as well as hypoglycemia
in patients receiving chronic analgesia with methadone78. Methadone-induced hypoglycemia was also noted in a
rodent model79. Paucity of comprehensive metabolic status assessments5 or of a proper control adjusting for OUD
and for an ongoing opioid agonist therapy6,69,73 may partially explain the divergent results. Other potential reasons
include the types of opioid receptors engaged36, their ligands79, the dose27,80, acute vs. prolonged opioid exposure36
and peripheral81,82 vs. central36,40 sites of action.
In sum, OUD patients are vulnerable to the development of glucoregulatory alterations that may be worsened
by the MAT agonists. Current therapy, focused on dietary caloric restriction, has limited efficacy83 and little is
known about potential correlates of metabolic dysfunction arising in the context of buprenorphine or methadone treatment. Albeit both agents display a high affinity for the µ receptors, buprenorphine is a partial agonist
owing to a distinctive association/dissociation profile contributing to its potentially diminished metabolic side
effects vs. methadone that acts as a full opioid agonist84,85. Moreover, buprenorphine is an antagonist- whereas
methadone is an agonist at the ĸ receptors84, a characteristic that may likewise improve the former’s metabolic
profile86,87. Methadone is further differentiated from buprenorphine by been a non-competitive antagonist at the
N-methyl-D-aspartate receptors88 that are normatively involved in the suppression of appetite89,90, which once
again may predispose for the excessive BWG.
Our prior work suggests that blockade of opioid receptors is associated with improved metabolic indices91,92
as well as with decreases in rewarding properties of sweet solutions93. Here we attempted to extend these findings and to examine the effects of the opposite hyperopioidergic state by employing comprehensive metabolic
assessment including plasma lipids, hemoglobin A1C, body composition, the oral glucose tolerance test (oGTT)
and the Sweet Taste Test (STT) in OUD patients on buprenorphine- or methadone maintenance. We hypothesized that given the differences in the opioid receptor binding properties, subjects treated with buprenorphine vs.
methadone would display more favorable metabolic characteristics and considering the alterations in metabolic
restraint on the reward centers48,94, subjects with- vs. without MetS would display a worse addiction severity. In
an exploratory fashion, potential relationships between the MAT drugs’ exposure duration with metabolic and
addiction indices were assessed separately in each study group.

Methods

Subjects. All experiments were performed in accordance with relevant guidelines and regulations. Fifty eight
subjects participating in MAT with either buprenorphine (n = 26) or methadone (n = 32) were recruited through
local advertising and gave written informed consent to the Cambridge Health Alliance (CHA) IRB-approved
protocol after the procedures were fully explained. The Diagnostic and Statistical Manual of Mental Disorders,
5th Edition OUD diagnosis was established via the best estimate format using all available sources of information,
including history, structured clinical interview with the Mini-International Neuropsychiatric Interview and the
Addiction Severity Index (ASI)95.
Subjects’ good physical health was determined by history, physical exam and the Cornell Medical Index
Health Questionnaire96. Weight was measured using a digital electronic scale and height with a Harpenden stadiometer, calibrated on a weekly basis. Body composition (lean and fat body mass) was determined by bioelectric
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impedance analysis (BIA; RJL Systems, Clinton Township, MI) as described elsewhere by our group91. Daily
physical activity was self-reported as none = 0, very light = 1, light = 2, moderate = 3, heavy = 4 and elite athlete = 5. Depressive symptomatology was self-rated with the Beck Depression Inventory97. The opioid craving
questionnaire was modeled after the cocaine craving assessment tool98 previously utilized by our group99, owing
to its ability to predict short-term drug consumption100. It measures key aspects of opioid craving (items rated on
a scale of 0–10), including (a) current intensity, (b) projected intensity, (c) resistance to opioid consumption, (d)
responsiveness to opioid-related conditioned stimuli, and (e) imagined likelihood of opioid consumption if in a
setting with access to it. Total spontaneous craving scores were derived by adding together ratings scores on items
1 and 4–6 and subtracting items 2 and 3 resulting in the maximal total score 40.
Subjects were excluded based on pregnancy or a diagnosis of dementia, bipolar disorder, schizophrenia spectrum disorder, major depression, drug/alcohol use disorder (other than OUD), or eating disorder. Also excluded
were subjects with potentially confounding medical conditions (e.g., diabetes mellitus, other endocrinopathy,
chronic obstructive pulmonary disease, congestive heart failure, hepatitis, hepatic failure, cirrhosis, HIV positive
status, end-stage kidney disease, use of opioid antagonists or agonists other than buprenorphine or methadone or
use within the past month of drugs with prominent orexigenic or anorexigenic effects e.g., psychostimulants, antihistamines, cannabinoids, dopaminergic or antidopaminergic agents, and mood stabilizers, antidepressants with
prominent catecholaminergic effects such as tricylclics, buproprion, mirtazepine, venlafaxine, and duloxetine) or
neurological conditions (e.g., seizure disorder, head trauma, past brain surgery, multiple sclerosis, or Parkinson’s
disease). Urine toxicology screens were used to confirm MAT adherence and to rule out recent drug (including
benzodiazepines) and alcohol consumption; the latter was also ruled out via breathalyzer. The dose was verified
by the MAT program and the prescription container label when appropriate.

Protocol. On the morning of the procedure, subjects reported to the CHA Outpatient Addiction Services,
after fasting and refraining from alcohol, tobacco, caffeine, or physical activity for >10 hours. Each of five concentrations of sucrose solution (0.05, 0.10, 0.21, 0.42, and 0.83 M) for STT was presented three times in a pseudorandom order, for a total of 15 samples. Subjects were instructed to sip the solution, swish it around in their mouths,
and spit it out. They were then asked to rate “How sweet was the taste?” and “How much do you like the taste?” on
a 100-mm analog scale, rinse their mouth with distilled water, and proceed to the next solution.
Glucose is the major energy source for the central nervous system that is neither stored nor produced there.
Hence is a need to reward and reinforce behaviors aimed at the procurement of this indispensable fuel that has
evolved as the primary reward. oGTT thus has an ecological validity in OUD patients as reward and reinforcement neural pathways is the key etiologic factor not only in food intake, but also in addiction21,48,101,102. While in
supine position, an intravenous catheter for oGTT blood sampling was placed into the antecubital fossa and kept
patent with a slow isotonic (0.9% w/v) saline drip. After resting for 30 minutes, subjects ingested Trutol (Glucose
Tolerance Test Beverage) containing 75 g of glucose (Fisher Scientific). Blood samples were collected at 15 minutes before (−15), immediately before glucose ingestion (0), and at 15, 30, 45, 60, 90, and 120 minute time-points.
Glucose and insulin plasma concentrations at −15 and 0 minutes were averaged to constitute a single baseline
value.
Biochemical assays. Assays were performed at the CHA Chemistry Laboratory. Plasma glucose concentration was quantified by the hexokinase assay (intra- and inter-assay coefficient of variation 2.00% and 3.00%,
respectively). Insulin was measured with the electrochemical luminescence immunoassay (intra-and inter-assay
coefficient of variation 1.9% and 2.60%, respectively). Plasma concentrations of total cholesterol (intra-and
inter-assay coefficient of variation 2.00% and 3.00%, respectively) and triglycerides (intra-and inter-assay coefficient of variation 2.00% and 2.00%) were measured using enzymatic methods. High- (intra-and inter-assay
coefficient of variation 2.3% and 2.7%, respectively) and low (intra-and inter-assay coefficient of variation 2.00%
and 4.00%, respectively) density lipoproteins (HDL and LDL, respectively) concentrations were determined via
the Siemens Healthineers’ ADVIA Chemistry Systems. High-performance liquid chromatography certified by the
Glycohemoglobin Standardization Program was used to measure hemoglobin A1C (intra-and inter-assay coefficient of variation 0.82% and 1.68%, respectively). Insulin resistance and beta-cell function were assessed with
the homeostasis model assessment, HOMA-IR and HOMA-β, respectively103. Whole-body insulin sensitivity was
estimated via the product of the plasma glucose and insulin concentrations during the oGTT quantified as the
area under the curve (AUC) using the trapezoid rule104,105.
Statistical analyses. Continuous drug exposure duration was computed as the number of defined daily
doses (DDDs) used by an average patient for the MAT indication i.e., 8 mg for buprenorphine and 25 mg for
methadone106 as the product of daily quantity and duration divided by the DDD for the respective agent107.
Independent samples t-tests (or Fisher’s exact tests as appropriate) were employed to analyze baseline demographic, clinical, anthropomorphic and biochemical measures’ differences (Table 1). To determine the effects of
glucose ingestion on glucose and insulin concentrations, a one-way analysis of variance (ANOVA) with repeated
measures design was conducted with the MAT agent (buprenorphine and methadone) as the grouping factor
and time (baseline, 15, 30, 45, 60, 90, and 120 minutes) as the within subjects factor. As time-effect was significant, post-hoc Newman – Keuls t-tests were performed to determine if and when changes from baseline were
significant.
General regression model analysis was performed using a model in which the independent variable was the
drug exposure duration with the MetS’ components as dependent variables. Both, post-hoc and exploratory
correlative analyses (for total cholesterol, LDL, hemoglobin A1C, and opioid craving) were conducted using
Pearson product-moment correlation. All analyses were two-tailed with α < 0.05 set as the threshold for statistical significance.
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Student’s t-test
t-value

p

Age (year)

39.92 (9.92)

41.17 (7.92)

−0.53

0.60

Education (year)

12.54 (1.36)

12.28 (0.99)

0.83

0.41

0.30 (0.14)

0.27 (0.11)

1.00

0.32

Total craving (score)

−5.13 (13.70)

−6.46 (10.59)

0.40

0.69

Total BDI (score)

20.52 (16.34)

21.07 (13.98)

−0.13

0.89

Smoking (cigarette/day)

8.44 (7.87)

9.57 (7.58)

−0.51

0.61

Daily physical activity (0–5)

1.54 (1.48)

1.78 (1.26)

0.68

0.50

14.85 (4.81)

78.34 (37.99)

n/a

n/a

694.80 (809.57)

937.50 (862.98)

−1.08

0.28

1272.00 (1445.12)

3036.41 (3560.73)

−2.33

0.02

29.21 (4.36)

30.32 (7.44)

−0.68

0.50

57.77 (17.00)

56.00 (29.42)

0.80

0.26

29 (11.27)

0.83

0.41

Variable

Buprenorphine

Demographic and clinical data

ASI (composite score; range
0–1.00)

Dose (mg)
MAT

Duration (day)
DDD (#)
BMI (kg/m2)
Body fat mass (kg)
Body fat mass (%)

Anthropometrics

Metabolic syndrome

32 (8.10)

Fat free mass (kg)

123.33 (15.22)

128.22 (23.63)

−0.87

0.39

Fat free mass (%)

68.45 (8.10)

70.75 (11.27)

−0.83

0.41

Total body water (kg)

42.05 (5.13)

43.65 (7.69)

−0.87

0.39

Total body water (%)

51.45 (6.03)

53.19 (8.57)

−0.83

0.41

Waist (cm)

101.06 (12.49)

102.98 (5.3)

−0.49

0.62

Triglycerides (mg/dL)

113.60 (68.72)

133.72 (62.80)

−1.12

0.27

49.39 (15.46)

38.97 (9.98)

3.00

0.004

Systolic BP (mmHg)

119.96 (11.04)

131.25 (21.66)

−2.38

0.02

Diastolic BP (mmHg)

75.15 (9.99)

81.18 (13.53)

−1.85

0.07

Glucosebaseline (mg/dL)

90.78 (13.62)

90.23 (21.78)

0.11

0.91

Glucose120 min (mg/dL)

98.56 (28.24)

108.81 (38.95)

−1.07

0.29

Insulinbaseline (mIU/L)

11.67 (9.16)

23.91 (53.02)

−1.23

0.22

Insulin120 min (mIU/L)

27.82 (22.17)

40.17 (34.16)

−1.52

0.14

2.76 (2.50)

3.87 (2.41)

−1.68

0.10

Total cholesterol (mg/dL)

173.27 (40.00)

165.04 (42.79)

0.74

0.47

LDL (mg/dL)

108.42 (35.84)

104.61 (44.11)

0.39

0.70

Hemoglobin A1C (%)

5.38 (0.44)

5.61 (0.65)

−1.51

0.14

HOMA-IR (pmol*mmol/L2)

2.69 (2.31)

7.10 (17.6)

−1.24

0.22

HOMA-β (%)

21.93 (704.36)

246.38 (297.98)

−1.47

0.15

MAP (mmHg)

90.09 (9.04)

97.87 (14.85)

−2.30

0.03

114114932 (110516922)

−2.10

0.04

HDL (mg/dL)

Triglycerides/HDL
Metabolic indices

GlucoseAUC * InsulinAUC
Taste_0.05 M (mm)

STT

Methadone

64727891 (39803279)
−0.30 (1.32)

−0.25 (1.73)

−0.12

0.91

Taste_0.1 M (mm)

0.23 (1.04)

−0.12 (1.44)

0.95

0.34

Taste_0.21 M (mm)

1.47 (1.57)

1.12 (1.42)

0.81

0.42

Taste_0.42 M (mm)

2.82 (0.98)

2.86 (1.73)

−0.08

0.94

Taste_0.83 M (mm)

3.88 (1.12)

4.28 (0.87)

−1.36

0.18

−0.32 (1.84)

−0.62 (2.36)

0.49

0.62

Like_0.1 M (mm)

0.00 (1.89)

−0.26 (2.29)

0.33

0.67

Like_0.21 M (mm)

0.54 (1.61)

0.54 (2.33)

0.39

0.70

Like_0.42 M (mm)

1.11 (2.01)

0.96 (2.60)

0.20

0.84

Like_0.83 M (mm)

1.65 (2.25)

1.01 (2.46)

0.70

0.49

Like_0.05 M (mm)

Fisher’s exact test
p

Ratios

Gender (F/M)

13/13

9/23

0.11

Race (W/B)

24/2

29/3

1.00

Marital status (S/P)

19/7

29/3

0.10

Employment (Y/N)

5/21

7/25

1.00

Metabolic syndrome (Y/N)

5/21

18/14

0.007

Table 1. Demographic, Clinical, Anthropomorphic and Biochemical Data of Buprenorphine (n = 26)- and
Methadone (n = 32)-treated Subjects. Data are presented as mean (SD) or ratios. ASI, Addiction Severity Index;
AUC, area under the curve; BMI, Body mass index; DDD, defined daily dose; HDL, High-density lipoprotein;
HOMA-IR, homeostasis model assessment-insulin resistance; HOMA-β, homeostasis model assessment-beta
cell function; LDL, low-density lipoproteins; Like_0.05 M, lowest sucrose solution concentration liking selfrating; M, Molar; MAP, mean arterial pressure; MAT, Medication-assisted treatment; STT, sweet taste test;
Taste_0.05 M, lowest sucrose solution concentration taste self-rating.
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Buprenorphine

Methadone

Variable

Multiple R

F

p

Multiple R

F

p

Waist

0.009

0.002

0.97

0.16

0.85

0.36

Triglycerides

0.20

0.99

0.33

0.52

11.46

0.002

HDL

0.48

6.98

0.001

0.49

9.68

0.004

MAP

0.09

0.18

0.68

0.42

6.52

0.02

Glucosebaseline

0.29

2.11

0.16

0.54

12.75

0.01

Table 2. Results of general regression model analysis of the relationship between drug exposure duration and
metabolic syndrome components; Wilks’ Lambda = 0.9.71; F = 1.56; p = 0.22 for buprenorphine and Wilks’
Lambda = 0.47; F = 6.14; p = 0.0006 for methadone. HDL, High-density lipoprotein; MAP, mean arterial
pressure.

Results

Table 1 presents demographic, clinical, anthropomorphic and metabolic data for the two groups. Buprenorphineand methadone-treated patients were not significantly different with respect to age, race, gender, educational,
marital and employment status, addiction severity, anthropomorphic measures, physical activity, opioid craving, depressive symptomatology, number of smoked cigarettes, fasting- and 120 min plasma glucose and insulin
concentrations, plasma concentrations of total cholesterol, triglycerides, LDL and hemoglobin - A1C. The proportions of subjects with underweight, normal weight, overweight and obesity108 was similar (p > 0.41) among
buprenorphine (0%, 15.4%, 42.3% and 42.3%) - and methadone (3.1%, 18.8%, 31.2% and 46.9%) - treated groups.
Subjects in both groups engaged in very light – light physical activity, and were mildly (buprenorphine: TG/
HDL > 2, fasting insulin> 8 uIU/mL and HOMA-IR > 1.5) to moderately (methadone: TG/HDL > 3, fasting
insulin> 10 uIU/mL and HOMA-IR > 2.5) insulin-resistant109.
Other than the expected solution concentration effect for self-reported taste detection (F = 88.70; p < 0.0001)
and for solution liking (F = 5.57; p < 0.003), averaged across the three tasting trials, there were no significant STT
group effect or group by concentration interaction (p > 0.44). There were no significant group differences when
the proportions (50% vs. 58%) of sweet likers i.e., the ones giving the highest liking rating to the highest sucrose
concentration (0.83 M) were compared110.
The groups differed with regard to the MAT drug exposure duration (buprenorphine < methadone).
Buprenorphine-treated patients presented lower systolic- and mean arterial blood pressure (MAP) and marginally lower diastolic blood pressure in conjunction with higher HDL concentrations and insulin sensitivity index.
The group HDL (p = 0.02), but not MAP (p = 0.14) or insulin sensitivity index (p = 0.17) differences remained
significant after the adjustment for the drug exposure duration via the analyses of covariance (ANCOVAs).
Inclusion of daily physical activity as an additional covariate in the HDL ANCOVA did not significantly alter the
group differences’ results (p < 0.02).
MetS was defined in accordance with the American Heart Association/National Heart, Lung and Blood
Institute Consensus Statement by three or more of the following criteria111: waist circumference >88 cm for
women and 102 cm for men, triglycerides ≥150 mg/dL, HDL <40 mg/dL for men and <50 mg/d for women,
blood pressure ≥130/85 mm Hg and fasting glucose ≥110 mg/dL8. In comparison to the methadone-treated
subjects, their buprenorphine-treated counterparts displayed lower rates of MetS (Table 1). Binary logistic
regression indicated that there was a significant association between having metabolic syndrome with the study
group (Somers’ D = 0.40, p = 0.004), but not with the continuous drug exposure duration (Somers’ D = 0.17,
p = 0.13). Subjects with vs. without MetS were maintained on a higher dose of the MAT agent (699.13 ± 484.18 vs.
353.24 ± 330.72; t = 3.12; p = 0.003), though for a similar period of time (28.74 ± 30.98 vs. 27.09 ± 26.75; t = 0.21;
p = 0.83). There were no differences (p = 1.0) in the proportion of sweet likers among those with (52%) and without (56%) MetS. There was a trend for a predicted a priori heightened ASI composite score in subjects with- vs.
without MetS (0.31 ± 0.12 vs. 0.26 ± 0.12; t = 1.72; p = 0.09).
Throughout the 120 minutes following glucose ingestion, both groups demonstrated robust increases (i.e.,
time effect) in plasma glucose (F = 34.31; p < 0.001) and insulin (F = 12.49; p < 0.001) concentrations. There
was a trend for insulin group effect (F = 3.25; p = 0.08), but no glucose group effect or group by time interaction
for both biochemicals (p > 0.55). Post-hoc Newman–Keuls tests revealed that plasma concentrations of glucose
and insulin significantly increased at 15 minutes (p < 0.002), peaked at 30 minutes (p < 0.0001) and remained
significantly elevated at 120 minutes (p < 0.006). Despite excluding participants with previously diagnosed diabetes, two methadone-treated subjects met diabetes criteria based on fasting plasma glucose (FPG) ≥ 126 mg/
dL; 120 minutes glucose concentration of one of these subjects was also in the diabetic range i.e., ≥ 200 mg/dL.
Three buprenorphine- and three methadone-treated patients had impaired FPG ≥ 110 mg/dL112. Two additional
subjects in each study group displayed impaired glucose tolerance values based on the 120 minute glucose within
the 140–200 mg/dL range.
As shown in Table 2, general regression model analysis revealed that methadone (Wilks’ Lambda = 0.47;
F = 6.14; p = 0.0006)-, but not buprenorphine (Wilks’ Lambda = 0.71; F = 1.56; p = 0.22) exposure duration was
a significant predictor of MetS. Post-hoc analyses using Pearson product-moment correlation detected that more
buprenorphine exposure duration was significantly associated with higher HDL concentration (Table 3); more
methadone exposure duration was conversely associated with less HDL-, but higher values of triglycerides, MAP,
and fasting glucose (Table 3). Additionally, methadone exposure duration positively correlated with hemoglobin A1C, while neither drug exposure duration correlated with total cholesterol- or LDL plasma concentrations
Scientific Reports |

(2020) 10:5617 | https://doi.org/10.1038/s41598-020-62556-0

5

www.nature.com/scientificreports

www.nature.com/scientificreports/
Buprenorphine
Variable
Waist
Triglycerides

r

t
0.009

−0.20

Methadone
p

r

Comparison

t

p

z

p

0.04

0.97

0.12

0.68

0.50

−0.40

0.35

−0.99

0.33

0.45

2.64

0.01

−2.37

0.009

HDL

0.48

2.64

0.01

−0.46

−2.66

0.01

3.56

MAP

−0.09

−0.42

0.68

0.38

2.11

0.04

−1.70

<0.05

0.29

1.45

0.16

0.64

4.20

0.0003

−1.57

0.06

Total cholesterol

−0.10

−0.51

0.62

−0.04

−0.23

0.82

0.49

0.31

LDL

−0.24

−1.17

0.26

−0.002

−0.01

0.99

−0.79

0.22

Glucosebaseline

Hemoglobin A1C
Total craving

<0.0001

0.26

1.27

0.22

0.69

4.90

<0.0001

−2.01

0.02

−0.52

−2.76

0.01

0.15

0.75

0.46

−2.46

0.007

Table 3. Pearson product-moment correlation coefficient between drug exposure duration with metabolic
syndrome components, hemoglobin A1C and opioid craving. HDL, High-density lipoprotein; LDL, Lowdensity lipoproteins; MAP, mean arterial pressure.

(Table 3). Lastly, buprenorphine-, but not methadone exposure duration inversely correlated with the total opioid
craving score. The differences between buprenorphine- and methadone groups’ correlation coefficients113 for triglycerides, HDL, MAP, fasting glucose, hemoglobin A1C, and for total craving were statistically significant. There
was a trend significance for the MAP correlation coefficients’ differences (Table 3).

Discussion

In comparison to buprenorphine-, methadone therapy was associated with heightened rates of MetS, which were
also greater (56% vs. 34%) than those in the general populace114. The observed MetS rates difference seemed to
reflect the respective plasma HDL concentrations and was potentially derived from the unique receptor binding
profiles rather than the drugs’ exposure duration. Other group differences such as blood pressure and insulin
sensitivity were actually attributable to the drugs’ exposure duration effects. Also, buprenorphine and methadone
did not differently affect the anthropometric measurements, addiction-related indices or food preference assessed
by means of the STT.
Our data further show that buprenorphine differs from methadone in some of its metabolic correlates.
Specifically, buprenorphine exposure duration was positively correlated with the HDL concentrations independently of the physical activity. By contrast, the HDL concentrations were negatively correlated with the
methadone exposure duration, which was as well positively correlated with several metabolic indices including
triglycerides, MAP, fasting plasma glucose and hemoglobin A1C. An opposite direction of correlations between
HDL and drug exposure duration in the study groups suggests that both drugs may be involved in mediating the
HDL changes. The correlational nature of the results, however, does not prove the direct MAT-HDL interactions.
Thus, it cannot be determined from our results whether HDL concentrations respectively increased or decreased
in buprenorphine and methadone-treated subjects as a direct result of the opioid (or other types of) receptors’
engagement or both were a function of lifestyle changes. Further studies exploring potential HDL effects induced
by the differential receptors binding profiles characterizing buprenorphine and methadone may help to clarify this issue. Nevertheless, our data are in agreement with a clinical study demonstrating improvements of an
HDL-related114 metabolic index, namely, hemoglobin A1C77, in buprenorphine-treated NIDDM patients.
Significant correlations between methadone drug exposure duration and HDL, MAP, fasting glucose and
hemoglobin A1C values are in accord with an earlier study showing that methadone dose was significantly correlated with the odds of having NIDDM68,69. Furthermore, our findings extend to the methadone exposure duration
the prior report on the predictability of MetS based solely on the exposure time5. Although there were methodological similarities between the latter5 and the current study (e.g., enrollment of methadone-treated OUD subjects and measures of MetS), there were also important differences, including a sample of buprenorphine-treated
patients and the focus on comprehensive clinical, anthropomorphic and biochemical assessments rather than on
the MetS per se. Thus, this independent replication supports the validity of the relationship between methadone
and MetS9.
The failure to find a significant relationship between methadone exposure duration and waist circumference,
total cholesterol and LDL suggest that methadone may play a less prominent role in the pathophysiological processes affecting cholesterol delivery/turnover or in the preservation of visceral fat evident in the waist circumference115. Indeed, there was no significant correlation between waist circumference and total- or LDL cholesterol
(p > 0.33); the correlation coefficients indicate that less than 2% of the variance was accounted for by these measures. More research is warranted to address the possibility that each measure captures independent aspects of
obesity and of other metabolic abnormalities.
All the same, our data are consistent with the proposition that variations in the methadone exposure adversely
affects triglycerides, HDL, blood pressure, insulin sensitivity and MetS as a whole. However, the lack of randomization suggests an additional interpretation that metabolically impaired people actually have a greater severity of
opioid addiction21 and are thus receiving a higher dose and a longer duration of the methadone therapy. Among
correlated factors we cannot determine which are primary and which are secondary using a cross-sectional
design. A more complex feedforward interaction is also possible wherein an ongoing opioid consumption brings
about metabolic derailments, which further fuel addictive behaviors.
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Marginally higher (i.e., trend significance) addiction severity in OUD comorbidity with MetS would support this sort of an interaction regardless of the primary index event. Of note, insulin mediates the homeostatic and reward systems’ cross-talk (impairment of which might underlie the chronically relapsing nature of
addictive disorders) and it has been successfully tried in nicotine116,117 and cocaine118 addiction. It would be of
interest to test whether insulin is also able to improve metabolic and reward dysfunction in patients with OUD.
Antihyperglycemic compounds as a class along with the long- and short-term anti-obesity drugs may have heuristic value as well. Metformin, for instance, was demonstrated to improve glucoregulatory mechanism via the
opioidergic system119. Orexin 19 and melanocortin120 systems may offer additional exploratory vistas. Such an
approach may have merits in patients who are at risk to develop MetS prior to the initiation of agonist MAT (i.e.,
primary prevention) or who are targeted for an early intervention in the presence of mild metabolic problems
(secondary prevention). This proposed strategy underscores the multi-problem nature of OUD and helps easing
unnecessary boundaries separating psychiatric and medical OUD formulations, thus fostering inter-disciplinary
therapeutic interactions13.
A switch from methadone to buprenorphine121 is an alternative or complementary strategy. The finding that
methadone exposure duration is unrelated to craving suggests a lingering relapse risk during methadone maintenance and emphasizes the significance of its integration with non-pharmacological interventions including
contingency management122 or mindfulness-based techniques123. A potentially beneficial effect of buprenorphine
on opioid craving begs further validation. This effect may have pivotal implications for behavioral pharmacology
because it could help explicating the currently inexact definition of pharmacodynamic mechanisms inherent in
the phenomenology and therapy of opioid craving. Better paradigms for craving research may follow on for the
possible benefit of addiction treatment.
The prevalence of overweight and obesity detected in the buprenorphine (84.6%)- and methadone
(78.1%)-treated groups was somewhat higher than the numbers (71.6%) reported across the United States124.
However, while some prior preclinical125 and clinical126,127 studies support the central opioidergic system involvement in the metabolic side effects of methadone, no such data are available for buprenorphine128, and no inferences can be made about buprenorphine’s central mechanisms (or lack thereof) of metabolic changes6 from this
investigation that was primarily focused on the direct comparison with methadone regarding metabolic and
addiction indices. However, before such effects to be investigated, it is first necessary to show that they exist. The
latter, and not the former, was the objective of the present study. Its methods may be applied in conjunction with
neuroimaging techniques48 in future studies in order to address the question of the central mechanisms involvement. Even so, peripheral measures are important because a considerable amount of animal data, where peripheral and central measures were collected simultaneously in the presence of an effective blood-brain barrier129,130,
suggest that plasma measures may reflect directionally similar changes in the brain 131–136. Therefore changes in
plasma biochemicals e.g., glucose and insulin135–138 in buprenorphine-treated patients may suggest analogous
changes in their brain.
Besides the cross-sectional design and the correlational nature of some of the results, discussed above, this
study has additional limitations inherent in the use of the DDD, STT, oGTT and bioelectric impedance. The DDD
is a statistically defined unit of measurement that facilitates the comparisons of drugs’ consumption across various geographic locales106. It may not necessarily reflect the prevailing prescribing patterns for OUD since 8 mg is
half of the target daily buprenorphine dosage139, while 25 mg is only about 20% of that for methadone140, which
could have affected the drug exposure duration comparison. This consideration would not affect the results of the
correlative analyses that were performed separately for each study group.
Opioid agonist enhance palatability of sweet food in humans and in laboratory animals21,93. This mechanism
alone would not explain the clear finding of similar sweet preference in methadone- and buprenorphine-treated
subjects and in those with- and without MetS. The STT employed sucrose solutions, but excessive sugar intake is
not an exclusive (or even predominant) dietary factor implicated in the development of overweight and obesity
when compared with saturated fat141,142. Although a more realistic stimulus for this study could have been some
type of highly palatable mix of macronutirents (e.g., a milkshake)143, we believe that it would be most useful to
first subdivide the process of food reward into basic subtypes. Each subtype can be then studied separately, thus
providing a sound footing for understanding a potential interaction between different macronutrients and their
role in the generalized rewarding nature of food and metabolic derailments.
Two participants were diagnosed with diabetes and more had impaired glucose tolerance based on the oGTT.
FPG, the most common tool for monitoring metabolic status, is predominantly a measure of hepatic glucose
production in a fasting state. Though more time-consuming and costlier than FPG, oGTT measures glucose
and insulin sensitivity related to food intake, which is more ecologically valid considering that patients spend
relatively little time in a fasting state. Other measures of insulin sensitivity and secretion (e.g., euglycemic and
hyperglycemic clamp) might provide greater flexibility for evaluation of associated abnormalities in intermediary
metabolism. The Frequently Sampled Intravenous GTT is probably the most efficient method for obtaining both
measures with sufficient precision to guide the direction for future studies in this area. Besides, measuring of visceral fat (abdominal magnetic resonance imaging)35 in addition to total body fat (bioelectric impedance) would
enable to determine whether substantial differences exist that should be pursued in more detail.
In conclusion, the presented results suggest that two MAT agonists, buprenorphine and methadone, share
similarities, but have important differences with regard to their metabolic profiles. Both drugs are associated
with overweight, obesity and insulin resistance. Owing, in part, to better HDL values buprenorphine, as compared with methadone, produces lower rates of MetS, which in turn tends to be accompanied by a greater addiction severity. Buprenorphine exposure duration may be associated with better HDL and opioid craving values.
Conversely, methadone-, but not buprenorphine exposure duration may be involved in the triglycerides-, HDL-,
blood pressure-, fasting glucose- and hemoglobin A1C adverse effects.
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Given the morbidity and mortality related to OUD, and the data demonstrating the efficacy of MAT, buprenorphine and methadone will remain as crucial interventions. The process of administering MAT may, however,
need to be adjusted. For example, potential for metabolic derangements should be included in the informed consent discussion prior to implementation of a treatment plan. Our findings further underscore the importance of
the focus on lifestyle issues such as diet and exercise. Given that buprenorphine is associated with fewer metabolic
irregularities and a beneficial craving effect, it should be considered the default first step if the agonist treatment
is considered. Finally, future studies are needed for elucidation the mechanism of MAT and its central nervous
system sequelae along with optimal metabolic screening and monitoring standards of MAT patients.
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